Dataset opportunity
13Therapeutics — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by 13Therapeutics, usable for Diagnostic AI and Computer Vision.
Score
67.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Acquire
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in diagnostics market was valued at USD 2.0 billion in 2025 and is projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7%.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-03
New blood marker could help track MS progression and monitor treatment response
news-medical.net ↗ - 📰press2026-08-03
KKR to take Integer private for $5.7B
medtechdive.com ↗ - 📰press2026-08-03
Netzhautchip PRIMA startet in 30 europäischen Ländern
devicemed.de ↗ - 📰press2026-08-03
Beyond the Status Report: Using LLMs to Reveal the True State of SaMD Development
medtechintelligence.com ↗ - 📰press2026-08-03
Webcast tonight: Autism & mental health comorbidities
medicalrepublic.com.au ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📣Press / announcement
Received over $10M in NIH peer-reviewed grants for research
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — licensing rights to clarify · PII/regulated
Buyer persona
Medical-AI & diagnostic-imaging companies
13Therapeutics holds a Medical Imaging Dataset containing preclinical and in-vitro images, supported by associated medical records and regulatory evidence. This data is structured for direct application in training and validating Diagnostic AI algorithms, with its core value derived from research exclusively licensed from Oregon Health and Science University (OHSU).
The data serves the rapidly expanding global AI in diagnostics market, which was valued at USD 2.0 billion in 2025 and is projected to reach USD 9.7 billion by 2033, growing at a CAGR of 21.7%. [5] Despite access complexities like non-standardized formats or limited team bandwidth for extraction, the rarity and unique research provenance of this dataset make it a high-value asset for AI developers aiming to compete in this high-growth sector. ⚠ Diligence (valuable data, access to negotiate): Data is derived from research exclusively licensed from Oregon Health and Science University (OHSU); Preclinical and in-vitro data may be stored in non-standardized laboratory formats; Small research team may have limited bandwidth for data extraction · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves 13Therapeutics holds a proprietary and research-grade dataset, validated through over $10M in federal SBIR grants and in-house preclinical testing. This unique collection of biological response data is ideal for diagnostic AI companies seeking to train and validate novel algorithms. In a global AI diagnostics market projected to reach $9.7 billion by 2033, this dataset offers a rare competitive edge for developing next-generation medical imaging solutions.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is exceptionally high, driven by the global AI in diagnostics market's rapid expansion at a 21.7% CAGR as companies race to develop superior diagnostic tools. [5]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License70
ownership=owned, licensing=rights_unclear
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — This is a small, preclinical-stage drug development company whose core business is creating peptide therapeutics, making the proprietary data from its research a dormant by-product and a strong fit. Issues: The company is very small, with only 4 employees listed, which may impact the scale of their data operations. [1]; Publicly available information, such as interviews and patent applications, appears to date back to around 2013, raising questions about the current level of op
- Deep Qualification80
⚠ needs review — The target is a drug development company holding preclinical data as a byproduct of its R&D; the data is not its core product, and its rights are likely restricted by an exclusive license from OHSU. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms the existence of proprietary biological response data, including medical imaging from preclinical animal models, which is highly sought after by AI developers for training models on novel biological effects.
Industrial data
The company's portfolio of patented peptides indicates ownership of the underlying research data, likely including time-series data from experiments tracking specific intracellular signaling pathways, which is invaluable for predictive modeling in drug discovery AI.
Regulatory records
Securing over $10M in multiple SBIR grants demonstrates a history of generating extensive, structured research data that has successfully passed rigorous federal review, a key quality signal for buyers needing reliable, well-documented datasets.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
13Therapeutics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in diagnostics market was valued at USD 2.0 billion in 2025 and is projected to reach USD 9.7 billion by 2033, at a CAGR of 21.7% (source: Grand View Research). [5]. Investment score 67.8/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Markennovy — Medical Imaging Dataset Opportunity
View opportunity →healthcareEndiatx — Medical Imaging Dataset Opportunity
View opportunity →healthcareAktiia — Sensor Telemetry Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- How a Data Transaction Works3 min read
- What you are entitled to sell3 min read
- 5 Mistakes That Drive Buyers Away3 min read